Johnson & Johnson rated at outperform by RBC

RBC Capital Markets analyst Phil Nalbone gave Johnson & Johnson an outperform, average risk, rating after the company's reported third-quarter sales of $13.287 billion were generally in line with expectations. The 7.9% sales growth was the highest reported top-line growth rate since the second-quarter 2005, according to the analyst. Earnings per share of $0.94 topped RBC's and the Street's consensus estimate of by one cent. The company's full-year earnings per share estimates are in the range of $3.72 to $3.74, representing 9% growth. Shares of the New Brunswick, N.J.-based pharmaceutical company were up $1.15, or 1.77%, at $66.08. (NYSE: JNJ)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.